MedTrace Logo

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

NCT03654703 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-08-31

No results posted yet for this study

Summary

No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML）patients. Investigators reasoned that this group of patients if they have been treated with ablative conditioning regimens for HSCT combined with PT/Cy, under the rapid of immune reconstitution will have better outcomes.

Conditions

  • Hematopoietic System--Cancer

Interventions

DRUG

Cyclophosphamide

cyclophophamide

Sponsors & Collaborators

  • Capital Research Institute of Pediatrics

    lead OTHER_GOV

Principal Investigators

  • Jia Y Qin, MD · Hematology and oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-01
Primary Completion
2018-07-01
Completion
2020-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03654703 on ClinicalTrials.gov